Ignite Creation Date:
2024-05-05 @ 5:28 PM
Last Modification Date:
2024-10-26 @ 9:32 AM
Study NCT ID:
NCT00464945
Status:
COMPLETED
Last Update Posted:
2012-08-15
First Post:
2007-04-23
Brief Title:
Wyeth Study To Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Phase 3 RandomisedActive-Controlled Double-Blind Trial Evaluating the Safety Tolerability and Immunogenicity of Manufacturing Scale 13-valent Pneumococcal Conjugate Vaccine
Status:
COMPLETED
Status Verified Date:
2012-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the safety tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate 13vPnC vaccine compared to pilot scale 13vPnC in healthy infants when given with routine pediatric vaccines
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None